$0.18▴ 0.00%
End-of-day close · 2026-05-04
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-90.34MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
-77.6%year over year
Weak
Revenue is contracting year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Sangamo Therapeutics, Inc. is pre-profit. It is still burning cash while pre-profit. Revenue is contracting year over year.
Key numbers
Valuation
EPS (TTM)$-0.38
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin-356.9%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$34.56M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days29 articles
18 bullish11 neutral0 bearish
[Latest] Global gRNA Market Size/Share Worth USD 2950 Million by 2034 at a 19% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
AI Disruption Reshapes Bioinformatics: Record Investment and Breakthrough Tools Signal a New Era for Drug Discovery and Precision Medicine
State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?
XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?
VHT vs. PBE: Which Health Care ETF Is the Better Buy?
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.